摘要
DEFENCATH^(®)(taurolidine/heparin,牛磺罗定/肝素)是美国食品药品管理局(FDA)批准的首款血液透析中心静脉导管封管液,含牛磺罗定和肝素2种成分,其中牛磺罗定对革兰阴性菌、革兰阳性菌及真菌具有广谱抗菌活性,还具有抗内毒素和外毒素的活性,且尚未观察到微生物耐药,安全性良好;肝素采用小剂量,可有效抗凝且出血风险低,两者相辅相成。该封管液有效降低了导管相关血流感染的发生率,具有较高的临床应用价值,将为维持性血液透析的肾衰竭患者提供更多选择。
DEFENCATH^(®)(taurolidine/heparin)is the first hemodialysis central venous catheter lock solution approved by the FDA.Taurolidine has broad-spectrum antibacterial activity against Gram-negative and Gram-positive bacterium and fungal species and anti-endotoxin and anti-exotoxin activities.Moreover,microbial resistance has not been observed,and the safety is good.Low-dose heparin is effective in anticoagulation and has a low risk of bleeding,and the two complement each other,clinical studies have reported that the catheter lock solution(CLS)effectively reduces the incidence of catheter-related blood stream infection(CRBSI),with good safety and significant clinical value.It will bring benefits to renal failure patients undergoing maintenance hemodialysis.
作者
刘红淼
赵中华
刘欢
赵方亮
李艳玲
LIU Hongmiao;ZHAO Zhonghua;LIU Huan;ZHAO Fangliang;LI Yanling(Department of Pharmacy,the First Hospital of Hebei Medical University,Shijiazhuang 050031,China;Pharmacology Center,Zhongqi Pharmaceutical Technology(Shijiazhuang)Co.Ltd.,China Shijiangzhuang Pharmaceutical Group,Shijiazhuang 050035,China)
出处
《医药导报》
CAS
北大核心
2024年第9期1457-1460,共4页
Herald of Medicine
